TrialAnnals of oncology : official journal of the European Society for Medical Oncology2016

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.

M Schuler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.